Future Perspectives: Key Trends Shaping the Spray-Dried Biologics Market Until 2029

The spray-dried biologics sector is on the brink of significant expansion, driven by scientific advancements and growing market demands. As biologics continue to evolve and their applications broaden, the industry is set to witness considerable growth and innovation in the coming years. Here, we explore the latest market size projections, key players, emerging trends, and important segments shaping the future of spray-dried biologics.

Projected Growth and Market Size of the Spray-Dried Biologics Industry
The spray-dried biologics market is forecasted to experience rapid expansion, reaching a value of $2.87 billion by 2029. This growth corresponds to a compound annual growth rate (CAGR) of 11.5%. Several factors contribute to this upward trend, including increasing demand for biologics that remain stable at room temperature over extended periods, substantial investments in large-scale biologics manufacturing facilities worldwide, and a growing preference for outsourcing formulation and processing services. Additionally, the rise in novel biologic drug classes requiring enhanced stabilization, expanding biologics pipelines in emerging markets, and a heightened focus on supply chain efficiency with a reduced reliance on cold-chain logistics further fuel market growth. Cutting-edge technological developments such as advanced particle engineering platforms, continuous spray-drying systems, precision droplet control, hybrid drying and encapsulation techniques, and innovative excipient formulations are among the key trends driving the industry forward.

Download a free sample of the spray-dried biologics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30401&type=smp

Key Factors Supporting Market Expansion in Spray-Dried Biologics
The demand for biologics that can be stored and transported without refrigeration is a major factor propelling the spray-dried biologics market. This requirement helps reduce costs and logistical challenges associated with cold-chain distribution.
Meanwhile, increased global investments in manufacturing capabilities for biologics are enabling companies to scale up production volumes, meeting the rising demand from healthcare providers and patients.

Important Players Leading the Spray-Dried Biologics Market
Several prominent companies dominate the spray-dried biologics landscape, including Thermo Fisher Scientific Inc., Evonik Industries AG, Lonza Group AG, GEA Group, Fareva Group, Almac Group Limited, Seqens Group, Fabbrica Italiana Sintetici S.p.A., CordenPharma International, Hovione FarmaCiencia SA, Veranova Inc., Pace Analytical Services LLC, Olon S.p.A., Nova Laboratories Ltd, Leukocare AG, Micro Sphere SA, Seran Bioscience LLC, CritiTech Particle Engineering Solutions LLC, Xedev BV, and BÜCHI Labortechnik AG.
A notable collaboration took place in May 2023, when Hovione, a Portugal-based CDMO specializing in spray drying and particle engineering, joined forces with Germany's H&T Presspart. This partnership focuses on advancing high-efficiency device technologies for delivering dry powder inhalation formulations. By leveraging Presspart's Sunriser capsule-based dry powder inhaler platform, Hovione aims to improve the performance and commercial readiness of engineered spray-dried and high-dose inhalation therapies.

View the full spray-dried biologics market report:
https://www.thebusinessresearchcompany.com/report/global-spray-dried-biologics-market-report

Current Innovations and Emerging Trends in the Spray-Dried Biologics Market
Companies in this market are actively adopting cutting-edge dosing technologies to enhance manufacturing precision. One such innovation is drum dosing technology, which improves dose accuracy, powder handling efficiency, and enables reliable large-scale capsule filling. This technique uses a rotating drum with precision-engineered cavities alongside vacuum-assisted powder transfer to ensure consistent low-dose filling and high throughput scalability.
For example, in February 2024, Catalent Inc., a US-based CDMO, upgraded its inhalation manufacturing facility with potent capsule-filling capabilities using drum-based dosing systems combined with in-line advanced mass verification. This upgrade offers real-time dose validation and controlled low-humidity processing, greatly enhancing production efficiency, product consistency, and readiness for commercial manufacturing of spray-dried biologic dry-powder inhalation therapies.

Segment Breakdown Driving the Spray-Dried Biologics Market
This report divides the spray-dried biologics market into several key segments:
1) By Product Type: Monoclonal Antibodies, Vaccines, Enzymes, Hormones, and Other Product Types
2) By Route of Administration: Oral, Inhalation or Pulmonary, Injectable, and Topical
3) By End-User: Hospitals, Research Institutes, Pharmaceutical and Biotechnology Companies, and Other End-Users

Further categorization within these segments includes:
- Monoclonal Antibodies such as Chimeric, Humanized, Fully Human, Bispecific, and Antibody Fragments
- Vaccines including Live Attenuated, Inactivated, Subunit, Toxoid, Viral Vector, and Recombinant Protein types
- Enzymes divided into Therapeutic, Digestive, Metabolic, Recombinant, and Replacement Enzymes
- Hormones covering Peptide, Protein, Steroid, Recombinant, and Growth Hormones
- Other Product Types encompass Blood Factors, Cytokines, Fusion Proteins, Nucleic Acid Therapeutics, and Cell Culture Media Proteins

Each of these categories reflects the diverse applications and evolving research within the spray-dried biologics market, contributing to its overall growth and innovation trajectory.

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.